


Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:**CLAIMS**

1-11. (Cancelled)

12. (New) A compound of formula (I):



wherein:

Ar is phenyl which can be optionally substituted by one or more groups selected from halogen, hydroxy, cyano, C₁-C₈ alkyl (itself optionally substituted by one or more hydroxy or cyano groups or fluorine atoms), CH₂-R²; CH₂O(CH₂)_nOC₁₋₆ alkyl, C₁-C₈ alkyl-NR³-R⁴;

R² is a 5 to 7-membered saturated ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, an aryl or 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from nitrogen oxygen and sulphur, each of which can optionally substituted by one or more substituents selected from hydroxyl or hydroxymethyl;

R³ is hydrogen or C₁₋₆ alkyl and R⁴ is C₁₋₆ alkyl optionally substituted by one or more groups selected from hydroxyl or phenyl;

n is 1 to 4;

R¹ is hydrogen or phenyl optionally substituted by halogen, C₁-C₈ alkoxy, C₁-C₈ thioalkyl or C₁-C₈ alkyl;

and pharmaceutically acceptable salts thereof.

13. (New) A compound according to claim 12 in which R¹ is hydrogen or phenyl optionally substituted by halogen, in particular fluoro or bromo.

14. (New) A compound according to claim 12 in which Ar is a phenyl or a group CH₂R² where R² is pyrrolidine, morpholine or imidazole each of which is optionally substituted as defined in claim 12.

15. (New) A compound according to claim 12 in which Ar is a group CH₂R² where R² is pyrrolidine, morpholine or imidazole each of which is optionally substituted by hydroxyl or hydroxymethyl, CH₂NR³-R⁴ where R³ is hydrogen or methyl and R⁴ is CH₂CH₂OH, CH₂(CH₃)CH₂OH, CH₂(phenyl)CH₂OH, CH₂CH₂(OH)phenyl, CH₂CH₂(OH)CH₂OH, or CH₂OCH₂CH₂OCH₂OH or Ar is phenyl optionally substituted by one or more ethyl or hydroxymethyl groups.

16. (New) A compound according to claim 12 in which the Ar group is substituted by C₁-C₈ alkyl and C₁-C₈ alkyl substituted by a hydroxy group, more preferably hydroxymethyl.

17. (New) A compound according to claim 12 which is:

4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;

4-{2-Ethyl-3-[(2-hydroxy-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;

4-(2-Ethyl-3-[(2-hydroxy-ethyl)-methyl-amino]-methyl)-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;

- 4-{2-Ethyl-3-[(2-hydroxy-1-methyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-{2-Ethyl-3-[(*S*)-(2-hydroxy-1-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-{2-Ethyl-3-[(2-hydroxy-2-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-(2-Ethyl-3-morpholin-4-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-[2-Ethyl-3-(3-hydroxy-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-[2-Ethyl-3-[(*R*)-2-hydroxymethyl-pyrrolidin-1-ylmethyl]-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-{3-[(2,3-Dihydroxy-propylamino)-methyl]-2-ethyl-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-(2-Ethyl-3-imidazol-1-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-[3-(2-Ethoxy-ethoxymethyl)-2-ethyl-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 2-(4-Bromo-phenyl)-4-(2-ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-(2-Ethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 2-(4-Chloro-phenyl)-4-(2-ethyl-3-hydroxymethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;
- 2-(4-Chloro-phenyl)-4-(2-ethyl-3-imidazol-1-ylmethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide;

4-(2-Ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide
or a pharmaceutically acceptable salt thereof.


18. (New) A compound of formula (I) as defined in claim 12 for use in therapy.

19. (New) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.

20. (New) A method of treating a disease or condition mediate by JAK3 which comprises administering to a patient in need of such treatment a compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof.

21. (New) A method according to claim 20 in which the disease or condition is asthma, host versus graft rejection/transplantation or rheumatoid arthritis.

22. (New) A process for the preparation of a compound of formula (I) as defined in claim 12 which comprises:
reaction of a compound of formula (II):



(II)

in which R^1 is as defined in formula (I) or is a protected derivatives thereof and L is a leaving group, with a compound of formula (III):



in which Ar is as defined in formula (I) or is a protected derivatives thereof,
and optionally thereafter:

- removing any protecting groups
- converting a compound of formula (I) into a further compound of formula (I)